Background: Kv␤1.3 subunit modifies the gating and the pharmacology of Kv1.5 channels, decreasing their sensitivity to block induced by drugs, suggesting that Kv␤1.3 competes with them for a binding site at Kv1.5 channels.
THE diversity of voltage-gated K ϩ (Kv) channels structure and function is enhanced by heteromultimerization of different ␣ subunits and by their association with accessory Kv␤ subunits, 1 forming complexes of four ␣ subunits and four ␤ subunits that modify the electrophysiologic characteristics of the ␣ subunit. Kv channels play critical roles in the electrical responses throughout the cardiovascular system, being responsible for establishing the resting membrane potential and cellular repolarization in heart and peripheral vascular beds. [2] [3] [4] Kv1.5 channels are widely represented in the cardiovascular system. 5 In the heart, the Kv1.5 protein has been located in human atrial and ventricular myocardium explanted from newborn and adult patients. 6 However, electrophysiologic studies 7, 8 have shown the absence of Kv1.5-like current in human ventricular myocytes. These results suggest that I Kur is the native counterpart to Kv1.5 channels in human atria, 9 -12 and therefore, it can contribute to the repolarization process of the human atrial action potential. 11, 12 It has been reported that the expression of Kv1.5 protein is reduced in atrial appendages of chronic atrial fibrillation patients, 13 and more recently, a familial form of atrial fibrillation has been attributed to a loss-of-function mutation in Kv1.5. 14 In the pulmonary vasculature, Kv1.5 plays a critical role in the oxygensensitive regulation of arterial tone. 15 Thus, there is significant interest in Kv1.5 as a potential pharmacologic target for diseases such as chronic atrial fibrillation and chronic hypoxic pulmonary arterial hypertension. In the human myocardium and in blood vessels, the expression of two ␤ subunits (Kv␤1.3 and Kv␤2.1) that show overlapping expression patterns with Kv1.5 has been demonstrated. The Kv␤2.1 subunit increases the degree of slow inactivation of the current, whereas Kv␤1.3 induces a fast and incomplete inactivation of the current. 16, 17 Both, Kv␤2.1 and Kv␤1.3 shift the midpoint of the activation curve toward more negative voltages and slow the deactivation process. 16, 17 In addition, Kv␤1.3 subunits modify the pharmacology of the Kv1.5 subunits, decreasing their sensitivity to block induced by bupivacaine, quinidine, and S0100176. 18, 19 Bupivacaine is an amide-type local anesthetic widely used for regional anesthesia 20 that exhibits a high cardiotoxicity, likely due to its ability to depress the intracardiac conduction velocity and cardiac contractility. 21 These effects have been related to its blocking properties of Na ϩ and Ca 2ϩ channels. 22, 23 Moreover, several cases of long QT (QT interval of the electrocardiogram) syndrome have been reported in animal models and in humans. 24 -26 These cardiotoxic effects have been related to its blocking properties of K ϩ channels. [27] [28] [29] [30] [31] Bupivacaine is a racemic drug, and its cardiotoxicity has been mostly related to the effects of its R(ϩ) enantiomer. 32 ,33 R(ϩ)-bupivacaine exhibits a higher potency for blocking cardiac Na ϩ channels and Kv1.5 channels, 28, 34, 35 whereas its potency to block human ether-a-go-go-related gene (HERG) channels is lower. 29, 31 Stereoselective bupivacaine interactions with Kv1.5 channels has been shown to involve at least three amino acids located at the S6 segment (T507, L510, and V514). 36 Mutation of L510 was previously reported to decrease channel block induced by quinidine, bupivacaine, and tetraethylammonium. 36 -38 Although leucine at position 510 is predicted to face away from the central cavity, it has been recently demonstrated that mutation of this residue to alanine prevents the interaction with Kv␤1.3 and, thus, its ability to induce N-type inactivation and to alter Kv1.5 channel gating. 18 If L510 determines bupivacaine stereoselectivity and it is also required for Kv␤1.3-induced inactivation, it could be hypothesized that the inactivating ball of the ␤ subunit and bupivacaine may compete for the same internal receptor site, as it has been suggested for quaternary ammonium derivatives. 39 Stereoselective interactions are very specific and suggest direct and specific three-dimensional relations in the receptor site. Therefore, possible changes in the degree of bupivacaine stereoselectivity on Kv1.5 and Kv1.5 ϩ Kv␤1.3 channels may help us to test this hypothesis. Preliminary results have been published in abstract form. 40 
Materials and Methods
The surgery of Xenopus laevis for the isolation of oocytes was approved by the Regierungspräsidium in Giessen, Germany.
Cell Transfection
Human Kv1.5 (Ϫ22 to 1,894 nt) and Kv␤1.3 (Ϫ53 to 1,500 nt) were inserted in tandem into the same pBK vector with the Kv1.5 subunit placed 3= to the Kv␤1.3 subunit and behind an internal ribosome entry sequence, thus generating a dual cistronic messenger RNA as previously described. 41 The pBK construct used for Kv1.5 alone has been described. 42 HEK293 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% bovine fetal serum, penicillin-streptomycin (Sigma-Aldrich, Alcobendas, Spain), and 1% nonessential amino acids. Transfection of Kv1.5 (0.3 g) or Kv1.5 ϩ Kv␤1.3 channel (0.3 g) and reporter plasmid CD8 (1.6 g) was performed by use of lipofectamine (10 l). Before experimental use, cells were incubated with polystyrene microbeads precoated with anti-CD8 antibody (Dynabeads M450; Dynal, Oslo, Norway), as previously described. 19, 43 Because HEK293 cells express endogenous Kv currents, the effects of R(ϩ)and S(Ϫ)bupivacaine on untransfected HEK293 cells and on HEK293 cells transfected only with Kv␤1.3 were analyzed. In these experiments, we observed that both bupivacaine enantiomers stereoselectively blocked the en-dogenous Kv channels. However, the degree of this stereoselective block was not modified by Kv␤1.3. Therefore, in these experiments, we observed that S(Ϫ)bupivacaine (50 M) blocked the Kv current of untransfected and of Kv␤1.3-transfected HEK293 cells by 69.2 Ϯ 5.1 and 67.2 Ϯ 0.9, respectively (n ϭ 3; P Ͼ 0.05). R(ϩ)-bupivacaine (10 M) blocked the Kv current present in untransfected and in Kv␤1.3-transfected HEK293 cells by 26.5 Ϯ 6.5 and 26.9 Ϯ 6.2, respectively (n ϭ 3; P Ͼ 0.05). These results indicate that the possible contribution of the endogenous Kv current on the effects of bupivacaine enantiomers is negligible.
Electrophysiologic Technique and Data Acquisition from HEK293 Cells
The intracellular pipette filling solution contained 80 mM K-aspartate, 50 mM KCl, 3 mM phosphocreatine, 10 mM KH 2 PO 4 , 3 mM MgATP, 10 mM HEPES-K, and 5 mM EGTA and was adjusted to pH 7.25 with KOH. The bath solution contained 130 mM NaCl, 4 mM KCl, 1.8 mM CaCl 2 , 1 mM MgCl 2 , 10 mM HEPES-Na, and 10 mM glucose and was adjusted to pH 7.40 with NaOH. Bupivacaine enantiomers (Astra, Södertälje, Sweden) were dissolved in distilled deionized water to yield stock solutions of 10 mM.
Currents were recorded using the whole cell configuration of the patch clamp technique with a patch clamp amplifier (Axopatch 200C patch clamp amplifier; Axon Instruments, Foster City, CA) and stored on a personal computer (TD Systems, Madrid, Spain) with an analog-todigital converter DigiData 1322A (Axon Instruments). pClamp version 9 software (Axon Instruments) was used for data acquisition and analysis. Currents were recorded at room temperature (21°-23°C) at a stimulation frequency of 0.1 Hz and were sampled at 4 kHz after antialias filtering at 2 kHz. The average pipette resistance ranged between 1 and 3 M⍀ (n ϭ 12). Gigaohm seal formation was achieved by suction (2-5 G⍀, n ϭ 12). After seal formation, cells were lifted from the bath, and the membrane patch was ruptured with a brief additional suction. The capacitive transients elicited by symmetrical 10-mV steps from Ϫ80 mV were recorded at 50 kHz and filtered at 10 kHz for subsequent calculations of capacitative surface area, access resistance, and input impedance. Thereafter, capacitance and series resistance compensation were optimized and, usually, 80% compensation of the effective access resistance was obtained. Microcal Origin 7.0 (Microcal Software, Northampton, MA) and custom-made programs were used to perform least-squares fitting and for data presentation.
Deactivation and inactivation were fitted to a biexponential process. Therefore, both processes were fitted to an equation of the form y ϭ A 1 exp(Ϫt/ 1 ) ϩ A 2 exp(Ϫt/ 2 ) ϩ C, where 1 and 2 are the system time constants, A 1 and A 2 are the amplitudes of each component of the exponential, and C is the baseline value. The voltage dependence of activation curves were fitted with a Boltzmann equation: y ϭ 1/[1 ϩ exp(Ϫ(E Ϫ E h )/s)], in which s represents the slope factor, E represents the membrane potential, and E h represents the voltage at which 50% of the channels are open. Drug-induced block was measured at the end of 250-ms depolarizing pulses from Ϫ80 to ϩ60 mV. The degree of inhibition obtained for each drug concentration was used to calculate the IC 50 and n H values from the fitting of these values to a Hill equation of the form 1/[1 ϩ (IC 50 /[D] nH ]. 28 
Two-electrode Voltage Clamp Recordings in Xenopus Oocytes
Polymerase chain reaction-based site directed mutagenesis and the human Kv1.5 (KCNA5) constructs for expression in Xenopus oocytes were previously described. 44 Complementary RNA (cRNA) for injection into oocytes was prepared with T7 Capscribe (Roche Diagnostics GmbH, Mannheim, Germany) after linearization with NheI. Estimates of cRNA quality and quantity were determined by gel electrophoresis and ultraviolet spectroscopy. Ovarian lobes were dissected from mature Xenopus laevis anesthetized with tricaine and treated with collagenase (1 mg/ml, Worthington, type II) in OR2 solution (82.5 mM NaCl, 2 mM KCl, 1 mM MgCl 2 , and 5 mM HEPES, pH 7.4) for 120 min. Isolated oocytes were stored at 18°C in ND96 recording solution (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl 2 , 1 mM MgCl 2 , and 5 mM HEPES, pH 7.4) plus Na-pyruvate (275 mg/l), theophylline (90 mg/l), and gentamicin (50 mg/l). Microelectrodes were fabricated from glass pipettes filled with 3 M KCl and had a resistance of 0.2-1.0 M⍀. Two to four days after injection of oocytes with cRNA, currents were recorded at room temperature (21°-23°C) with standard two-electrode voltage clamp techniques.
Statistical Analysis
Data are presented as mean Ϯ SEM. Comparisons between mean values in control conditions and mean values in the presence of drug for a single variable were performed by use of the paired Student t test. One-way analysis of variance was used to compare more than two groups. Statistical significance was set at P Ͻ 0.05. The curve-fitting procedure used a nonlinear least-squares (Gauss-Newton) algorithm; results were displayed in linear and semilogarithmic format, together with the difference plot. Goodness of fit was judged by the chi-square criterion and by inspection for systematic nonrandom trends in the difference plot. Figure 1 shows original records of K ϩ current through Kv1.5 channels expressed in HEK293 cells in the absence and in the presence of S(Ϫ)or R(ϩ)-bupivacaine (50 M). Cells were held at Ϫ80 mV, and 250-ms depolarizing pulses to ϩ60 mV in 10-mV steps were applied at a frequency of 0.1 Hz. Tail currents were recorded at Ϫ40 mV. S(Ϫ)and R(ϩ)-bupivacaine blocked Kv1.5 channels by 48 Ϯ 6% (n ϭ 4) and 87 Ϯ 3% (n ϭ 5; P Ͻ 0.05), respectively, when measured at the end of the 250-ms depolarizing step to ϩ60 mV. Figure 2 shows current records through Kv1.5 ϩ Kv␤1.3 channels expressed in HEK293 cells obtained in the absence and in the presence of S(Ϫ)or R(ϩ)-bupivacaine (50 M) after applying the same pulse protocol. Kv␤1.3 produced an initial fast and incomplete inactivation of the current that exhibited a time constant of 3.8 Ϯ 0.4 ms (n ϭ 12) as previously described. 16, 19 Potency of bupivacaine enantiomers to block Kv1.5 ϩ Kv␤1.3 decreased with respect to that observed in Kv1.5 channels. 19 Therefore, R(ϩ)and S(Ϫ)-bupivacaine at 50 M decreased the current amplitude when measured at the end of 250-ms depolarizing pulses to ϩ60 mV by 66 Ϯ 2% (n ϭ 5) and 35 Ϯ 3% (n ϭ 8; P Ͻ 0.05), respectively. Figure 3A shows the current-voltage relations obtained after plotting the Kv1.5 current amplitude measured at the end of 250-ms depolarizing pulses at different membrane potentials between Ϫ80 and ϩ60 mV in the absence and in the presence of R(ϩ)or S(Ϫ)-bupivacaine. Both enantiomers decreased the magnitude of the current at all membrane potentials tested, and this block increased as the test potential was more positive. Thus, block was significantly higher when cell membrane was depolarized to ϩ60 than when it was stepped to 0 mV (48.4 Ϯ 5.9 vs. 37.4 Ϯ 5.5%, n ϭ 4, P Ͻ 0.05 and 83.6 Figure 5A (top) shows normalized Kv1.5 current traces obtained in the absence and in the presence of 10 M R(ϩ)or S(Ϫ)-bupivacaine after applying 250-ms depolarizing pulses to ϩ60 mV from a folding potential of Ϫ80 mV. Concentrations higher than 1 M R(ϩ)-bupivacaine induced a fast initial decline of the current that was superimposed onto the slow inactivation (figs. 1 and 5). The time constant of this drug-induced initial current decline was faster at higher concentrations, and therefore, it was considered as a good index of the kinetics of block ( B ). Figure 5A Similarly to what happened in Kv1.5 channels, the dissociation rate constants resulted to be similar for both enantiomers, and therefore, stereoselectivity may derive from differences in the association rate constants. Figure 6 summarizes the degree of stereoselectivity observed in Kv1.5 and Kv1.5 ϩ Kv␤1.3 channels. As can be observed, the degree of stereoselectivity decreases in a parallel manner to the ratio of the association rate constants and independently from the dissociation rate constants, which are similar for both enantiomers either in the absence or in the presence of the Kv␤1.3 subunit.
Results
Time dependency was also observed in the deactivation process of the current ( fig. 7) . Under control conditions, the deactivating process of Kv1.5 channels was best fitted to a biexponential process with slow ( s ) and fast ( f ) time constants. On the contrary, the deactivating process of Kv1.5 ϩ Kv␤1.3 channels was monoexponential, as previously reported. 19, 42 In both experimental conditions, the deactivation became slower in the presence of either bupivacaine enantiomer, as can be observed in figure 7 and in table 1. Moreover, in all cases, a "crossover" phenomenon indicative of an open channel block interaction was also observed. 28, 45 All these results could be explained if both, the inactivating Kv␤1.3 particle and bupivacaine compete for a receptor site, in which case, bupivacaine enantiomers would be able to slow down the N-type inactivation induced by the Kv␤1.3 subunit. In fact, as it is shown in figure 8 
Effects of Bupivacaine Enantiomers on S6 Mutant Kv1.5 Channels with or without Kv␤1.3
To directly analyze the possible competition between bupivacaine and the Kv␤1.3 subunit, we studied the inhibition induced by bupivacaine enantiomers of wild-type Kv1.5 and mutant Kv1.5 channels in the ab- Kv␤1.3 channels induced by S(؊)-and R(؉) S(؊)-and R(؉)-bupivacaine (from 10 to 1,000 M) . Each point represents the mean ؎ SEM of three to seven experiments. The solid line represents the fit from which the apparent binding and unbinding rate constants were obtained.
-bupivacaine. Top: Relation between the sensitive current and depolarizing time at three different bupivacaine enantiomers concentrations. Bottom: Relation between 1/ B values at different
sence and presence of Kv␤1.3, using two electrode voltage clamp recordings in Xenopus oocytes. We focused on two residues at the S6 level previously described as part of the bupivacaine binding site, L510 and V514. 36 To test whether these residues also mediate the loss of stereoselectivity induced by Kv␤1.3, we studied the inhibition potencies of the bupivacaine enantiomers for these mutants alone or in presence of Kv␤1.3. Overall bupivacaine affinity was reduced compared with recordings in HEK293 cells, a phenomenon previously described for Xenopus oocytes and other drugs. Similar as in HEK293 cells, the R(ϩ) enantiomer was more potent blocking wild-type Kv1.5 channels, and stereoselectivity was reduced in the presence of Kv␤1.3 (fig. 9A ). The mutations L510A and V514A preserved the stereoselec-tivity in the absence of Kv␤1.3 (figs. 9B and C), as previously described. 36 In the presence of Kv␤1.3, stereoselectivity was abolished for V514A mutant channels but not for L510A. The residue L510 is, in contrast to V514, a part of the Kv␤1.3 binding site 18 and the bupivacaine binding site. 36 Consistently, the Kv␤1.3 mediated reduction in stereoselectivity was not present for the L510A mutation ( fig. 9B ), which lacks inhibition by Kv␤1.3.
Discussion
In the current study, we have analyzed and compared the interactions between bupivacaine enantiomers and Kv1.5 or Kv1.5 ϩ Kv␤1.3 channels transiently expressed in HEK293 cells. The main findings of the current study are as follows: (1) the potency of both bupivacaine enantiomers to block these currents decreases when Kv␤1.3 is present; (2) the decrease in potency is higher for R(ϩ)-bupivacaine than for S(Ϫ)-bupivacaine; (3) the degree of stereoselective block of Kv1.5 channels decreases from 9 to 4 when the Kv1.5 subunit is assembled with Kv␤1.3; (4) bupivacaine enantiomer slow the time . 6 . Relation between the degree of stereoselective bupivacaine block (), the association rate constants ratio for bupivacaine enantiomers, and the dissociation rate constants ratio for both bupivacaine enantiomers. Note that the decrease of the degree of stereoselectivity is accompanied by a parallel decrease in the association rate constants ratio and that is independent of the dissociation rate constant ratio. Finally, the time course of deactivation became slower in the presence of either bupivacaine enantiomer and, after superimposing control and bupivacaine tail currents, a "crossover" of the currents, indicative of an open channel block mechanism, was observed. 28, 45, 46 Bupivacaine enantiomer-induced block of Kv1.5 ϩ Kv␤1.3 channels seems also to be the consequence of an open-channel interaction. Similarly to that observed in Kv1.5 channels, (1) bupivacaine enantiomers produced an initial current decline that was faster as the drug concentration was increased; and (2) the time course of deactivation became slower in the presence of either bupivacaine enantiomer, and after superimposing control and bupivacaine tail currents, a "crossover" of the currents was observed. However, block was not voltage dependent. In fact, the IC 50 for R(ϩ)and S(Ϫ)-bupivacaine when measured at the end of 250-ms depolarizing pulses from Ϫ80 to 0 mV were 17.0 Ϯ 3.4 M (vs. 17.2 Ϯ 2.2 M when measured at ϩ60 mV; P Ͼ 0.05) and 81.7 Ϯ 30.1 M (vs. 71.9 Ϯ 11.5 M when measured at ϩ60 mV; P Ͼ 0.05). This lack of voltage-dependent block of Kv1.5 ϩ Kv␤1.3 channels induced by bupivacaine enantiomers may be due to the competition between the bupivacaine molecule and Kv␤1.3. In fact, it has been described that the inactivation of Kv1.5 induced by Kv␤1.3 exhibits a voltage dependency similar to that induced by bupivacaine enantiomers in Kv1. 5, 42, 47 which supports the hypothesis of a competition between bupivacaine and Kv␤1.3.
Stereoselective Block of Kv1.5 and Kv1.5 ϩ Kv␤1.3 Channels Induced by Bupivacaine
The results presented in this study demonstrate that bupivacaine enantiomers block Kv1.5 and Kv1.5 ϩ Kv␤1.3 channels in a stereoselective manner. The degree of stereoselectivity decreases from a value of 9 to 4, when examined in Kv1.5 and Kv1.5 ϩ Kv␤1.3 channels, respectively. The IC 50 values obtained from the block induced by bupivacaine enantiomers of Kv1.5 and Kv1.5 ϩ Kv␤1.3 channels can be assumed as a good approximation of the apparent dissociation constant (K D ) values, which can be converted into apparent binding energies (⌬G) relative to a 1 M standard concentration using the relation
where R is the universal gas constant and T is the absolute temperature. The free energy indicates the relative stability of the drug-channel complex. The values for ⌬G were Ϫ7.20 and Ϫ5.91 kcal/mol for Kv1.5 block induced by R(ϩ)and S(Ϫ)-bupivacaine, respectively, and Ϫ6.40 and Ϫ5.57 kcal/mol for Kv1.5 ϩ Kv␤1.3 block induced by R(ϩ)and S(Ϫ)-bupivacaine, respectively. Therefore, the difference in the degree of stereoselectivity between Kv1.5 and Kv1.5 ϩ Kv␤1.3 channels corresponds to a difference in free energy of 1.31 and 0.83 kcal/mol between R(ϩ)and S(Ϫ)-bupivacaine blocked channels, respectively. This may reflect a more stable interaction of the R(ϩ)-bupivacaine with the channel. However, differences in potency between both enantiomers were largely explained by their different association rate constants, which were faster for R(ϩ)bupivacaine in both experimental conditions. Because these drugs are enantiomers, most of their properties are identical, including the free energy associated with similar mirror image conformations. Therefore, differences in association rate constants suggest that the S(Ϫ) enantiomer needs to adopt a less favorable conformation, i.e., 1.31 and 0.83 kcal/mol above the conformation in which R(ϩ)-bupivacaine binds to Kv1.5 and Kv1.5 ϩ Kv␤1.3 channels, respectively. All these results, together with the fact that both enantiomers, at low concentrations, slow down the fast inactivation induced by Kv␤1.3, can be explained by a competition mechanism between bupivacaine enantiomers and Kv␤1.3.
Partial Overlap between Kv␤1.3 and Bupivacaine
Binding Site in Kv1. 5 From the results obtained in mutant Kv1.5 channels alone or assembled with Kv␤1.3 subunit, we conclude that Kv␤1.3 reduces the stereoselectivity of bupivacaine block, by a direct binding to the inner cavity of the Kv1.5 channels. The L510A mutant (in contrast to L510M) preserves stereoselectivity of bupivacaine block 36 while inhibition by Kv␤1.3 is diminished. 18 As L510A is a part of the Kv␤1.3 binding site, 18 the mutant L510A channels are not blocked by Kv␤1.3. Accordingly, Kv␤1.3 is not able to eliminate the stereoselectivity of bupivacaine block. In contrast, the stereoselectivity of mutant V514A channels, which have an intact Kv␤1.3 binding ability, 18 remains modulated by the inhibition of Kv␤1.3. The residue L510 is particularly important for the modulation of bupivacaine block, because from our current knowledge L510 is the only residue of the S6 segment that is binding to both bupivacaine 36, 37 and Kv␤1.3. 18 These findings support our previous reports of an overlapping binding site for drugs and Kv␤1.3 18, 19 and pinpoint the stereoselective effects of Kv␤1.3 to the S6 segment residue L510.
Previous studies have analyzed the pharmacologic consequences of the assembly of HERG ϩ MiRP1 and Kv4.3 ϩ KChIP2.2. 30,48,49 Whereas MiRP1 did not modify the degree of block produced by bupivacaine in HERG channels, bupivacaine interfered with the effects of KChIP2.2 on Kv4.3. The results obtained in the current study demonstrate that bupivacaine and Kv␤1.3 compete for a binding site that overlaps for bupivacaine and Kv␤1.3 at the inner cavity of the Kv1.5 channel. This unique feature observed in Kv1.5 ϩ Kv␤1.3 seems to be the consequence of their interaction, because the N-terminus of the ␤ subunit (like bupivacaine and other antiarrhythmic drugs) blocks the open state of Kv1.5 channels, whereas KChIP2.2 assembly to the N-terminal tetramerization (T1) domain of Kv4.3, it does not interact with the ion pore of the channel. 50 
Clinical Consequences of This Study
The degree of stereoselective bupivacaine block of Kv1.5 ϩ Kv␤1.3 channels strongly decreases with respect to the stereoselective block of Kv1.5 channels (from 9 to 4). The differences in free energy of bupivacaine enantiomers for blocking Kv1.5 and Kv1.5 ϩ Kv␤1.3 channels correspond with 0.80 and 0.34 kcal/ mol for R(ϩ)and S(Ϫ)-bupivacaine, respectively. These differences reflect a more stable interaction between bupivacaine enantiomers with Kv1.5 than with Kv1.5 ϩ Kv␤1.3 channels, as observed by the higher dissociation rate constants obtained for the interaction with Kv1.5 ϩ Kv␤1.3 channels. However, the difference in free energy mostly affects to the more potent blocker, R(ϩ)-bupivacaine. It has been described that the levels of Kv␤1.3 expression vary in the different heart regions and also in different smooth muscle cells. 16, 51 Kv␤ subunits can modulate the pharmacology of Kv1 channels in addition to their well-characterized ability to alter channel gating and expression. For example, Kv␤1.3 subunits reduce the block of Kv1.5 by racemic bupivacaine, quinidine, and S0100176. 18, 19 Previous findings suggested that S0100176 and the Kv␤1.3 subunit compete for an overlapping but not identical binding site located in the inner cavity of Kv1.5. 18 Moreover, the Kv1.5 pore-blocker AVE0118 interacts with a similar subset of residues at the S6 than S0100176 including residues L510 and V516, similar to the binding of Kv␤1.3. 52 The current study demonstrates that the assembly of Kv1.5 and Kv␤1.3 subunits decreases the block induced by bupivacaine enantiomers and also the degree of stereoselectivity. Therefore, the sensitivity to Kv1.5 channel blocking drugs will vary depending on the regional distribution of ␤ regulatory subunits. The expression of Kv␤1.3 subunits in the myocardium is not homogeneous, for this subunit is expressed to a higher degree in the ventricle than in atria. 53 Similarly to Kv␤1.3, KChIP2.2 subunits show a gradient of expression in cardiac ventricle, and it has been suggested that this ancillary subunit influences the effects of local anesthetics on Kv channels. 49 In accordance, Kv␤1.3 might affect bupivacaine block of Kv1.5 channels in a transmural fashion. Moreover, a Kv␤1.3 gradient might be important for the transmural distribution of K ϩ channels, especially because Kv␤1.3 might be influencing the expression of a variety of Kv channels. 54 Within various vascular beds, there are marked differences in ␤ subunit expression, whereas Kv1.5 levels change little. 51 Therefore, the differential assembly between the Kv␣ and Kv␤ subunits present in the cardiovascular system is a variable to be accounted for the development of new ion channel modifying agents and can account, at least partially, for the less cardiotoxicity observed with S(Ϫ)-bupivacaine.
